Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005)
Clinical Lung Cancer · 2024
DOI: 10.1016/j.cllc.2024.07.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lung Cancer, 2024. Verfasst von Hayato Kawachi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Osaka, Japan; Department of Pulmonary Medicine, Graduate School of Medi…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Chemoradiotherapy, Antibodies, Monoclonal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: The optimal subsequent treatment strategy for locally advanced non-small cell lung cancer (LA-NSCLC) after chemoradiotherapy (CRT) and consolidative durvalumab therapy remains unknown. We aimed to determine the optimal subsequent treatment strategy for this clinical population. MATERIALS AND METHODS: We retrospectively enrolled 523 consecutive patients with LA-NSCLC treated with CRT and analyzed the treatment outcomes of subsequent therapy after progression following CRT and consolidative durvalumab therapy. Patients who received tyrosine kinase inhibitors as subsequent therapy were excluded. RESULTS: Out of 122 patients who received subsequent chemotherapy, 55% underwent platinum-based, 25% non-platinum-based, and 20% immune checkpoint inhibitor (ICI)-containing therapies. In the platinum-based group, patients with a durvalumab-progression-free survival (Dur-PFS) ≥ 1 year had a significantly longer median subsequent therapy-PFS (SubTx-PFS) than those with Dur-PFS < 1 year (13.2 months vs. 4.7 months; hazard ratio, 0.45; 95% confidence interval, 0.21-0.97; P = .04). Furthermore, among patients receiving non-platinum-based chemotherapy, the median SubTx-PFS was longer in the combined with angiogenesis inhibitor group than in the without group, although the difference was not statistically significant. No significant difference of SubTx-PFS was observed between the reason for durvalumab discontinuation and the outcomes of ICI-containing therapy. CONCLUSION: In clinical practice, platinum-based chemotherapy rechallenge is frequently employed following progression subsequent to CRT and consolidative durvalumab therapy for LA-NSCLC. Optimal treatment strategies may consider Dur-PFS and angiogenesis inhibitor feasibility. Further research is warranted to identify clinical biomarkers that can help identify patients who would benefit from ICI rechallenge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Osaka, Japan; Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Kyoto, J…
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Osaka, Japan.
- Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Department of Respiratory Medicine, Fujita Health University, Toyoake, Aichi, Japan.
- Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan.
- Department of Internal Medicine, NHO Kinki Chuo Chest Medical Center, Sakai, Osaka, Japan.
- Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan.
Zitieren
APA
Kawachi, H., Tamiya, M., Oya, Y., Saito, G., Taniguchi, Y., Matsumoto, H., Sato, Y., Otsuki, T., Suzuki, H., Fukuda, Y., Tanaka, S., Tsukita, Y., Uchida, J., Sakata, Y., Nakatani, Y., Shibaki, R., Arai, D., Okada, A., Hara, S., …, & Nishino, K. (2024). Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005). Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2024.07.014
Vancouver
Kawachi H, Tamiya M, Oya Y, Saito G, Taniguchi Y, Matsumoto H, et al. Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005). Clinical Lung Cancer. 2024. doi:10.1016/j.cllc.2024.07.014
BibTeX
@article{Kawachi2024,
author = {Kawachi, Hayato and Tamiya, Motohiro and Oya, Yuko and Saito, Go and Taniguchi, Yoshihiko and Matsumoto, Hirotaka and Sato, Yuki and Otsuki, Taiichiro and Suzuki, Hidekazu and Fukuda, Yasushi and Tanaka, Satoshi and Tsukita, Yoko and Uchida, Junji and Sakata, Yoshihiko and Nakatani, Yuki and Shibaki, Ryota and Arai, Daisuke and Okada, Asuka and Hara, Satoshi and Takayama, Koichi and Nishino, Kazumi},
title = {Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005)},
journal = {Clinical Lung Cancer},
year = {2024},
doi = {10.1016/j.cllc.2024.07.014}
}
EUVIMED